In Search for a Cure: Are We Nearing a Treatment for COVID-19?

• The Milken Institute Summer Series concluded with a focus on the global COVID-19 pandemic, noting over 120,000 deaths in the U.S. and nearly 500,000 globally, with significant disparities impacting communities facing structural inequalities.
• The 23rd Global Conference is tentatively scheduled for October, with organizers acknowledging that an in-person event is increasingly unlikely, though a robust online format is being prepared as a contingency.
• Faster Cures, the Milken Institute's center for medical solutions, is tracking nearly 250 treatment compounds and 170 vaccine candidates in various stages of testing, with data updated daily on their website.

Current Epidemiological Status (Dr. Anthony Fauci)

• The U.S. is experiencing a "serious turnaround" with record daily infections, driven by a heterogeneous spread where regions like Florida, California, Arizona, and Texas are seeing surges despite earlier successful suppression.
• Infection demographics have shifted to be dominated by younger individuals, who may not require hospitalization themselves but pose a high risk of transmitting the virus to vulnerable, older populations, creating a lag in observed mortality rates.
• The resurgence is attributed to a combination of premature reopenings, a public psychological shift viewing restrictions as an "all-or-none" phenomenon, and a failure to adhere to fundamental protocols like masking and social distancing.
• Contact tracing efforts are struggling due to a lack of personnel, public non-cooperation, and the difficulty of isolating asymptomatic carriers; Fauci advocates for "pooling" testing (testing groups of 20–40 samples together) to increase efficiency and scale.
• CDC serology surveillance suggests that roughly 10 times as many people have been infected as officially confirmed, a figure Fauci describes as "sobering" rather than good news, necessitating a massive increase in community testing to manage outbreaks.
• Fauci warns that warm weather is not preventing surges and emphasizes that the U.S. is still in the first wave, with a high probability of significant surges in the fall requiring robust preparedness for identification, isolation, and tracing.
• Regarding protests, Fauci states that while definitive causal proof is difficult to establish amidst other variables, congregations without masks that involve shouting or chanting significantly increase the risk of transmission.
• Fauci anticipates a vaccine with 70–80% efficacy could be available by the end of 2020 or early 2021, with companies targeting hundreds of millions of doses by year-end and potentially a billion by 2021, though he cautions that widespread availability does not permit the abandonment of public health measures.
• Phase III clinical trials for the leading vaccine candidates are scheduled to begin in the U.S. in July, with enrollment expected to conclude by early fall, with results on efficacy and safety likely available in late fall or early winter.
• Safety monitoring in trials will specifically focus on "antibody-dependent enhancement" (ADE), a rare phenomenon where a vaccine could theoretically worsen the infection, though current animal data does not indicate this risk.
• Dexamethasone has been added to NIH guidelines as standard of care for advanced disease requiring ventilation, based on recent trial data.
• Fauci emphasizes that future treatments and antibody therapies will likely require combination "cocktails" to prevent viral evasion, similar to HIV treatment protocols.

Pfizer Vaccine Development and Strategy (Dr. Albert Bourla)

• Pfizer, in collaboration with BioNTech, is utilizing mRNA technology to develop a vaccine, a platform chosen for its speed in replication and ability to adapt to viral mutations compared to other platforms.
• Pfizer projects safety and efficacy data from a large-scale Phase III trial of approximately 30,000 participants could be available by September, with a potential FDA approval request in October if data is favorable.
• The Phase III trial will be conducted globally but predominantly in the U.S., utilizing hundreds of experienced clinical sites in high-burden areas like Florida, Arizona, and Texas to accelerate event accumulation.
• Pfizer is manufacturing vaccine doses at risk, projecting tens of millions of doses by the end of 2020 and potentially up to one billion doses in 2021, contingent on trial success and lack of significant obstacles.
• Unlike some government partners, Pfizer has declined direct funding from the U.S. government or BARDA for the vaccine development to maintain operational autonomy and speed, though the company collaborates with Operation Warp Speed on logistics and distribution.
• Pfizer is establishing separate manufacturing supply networks for the U.S. and Europe but acknowledges the need to address global equity and infrastructure challenges, particularly regarding cold-chain requirements for mRNA vaccines in developing nations.
• Pricing strategy will not be based on the economic value of saved hospitalizations or GDP, as that would be unethical; instead, prices will align with existing vaccine markets, with potential discounts for high-volume purchasing, while still anticipating profitability.
• Bourla stated that the decision to avoid government funding was made to prevent potential slowing of the process due to accountability requirements, prioritizing "return on effort" over "return on investment."
• Pfizer asserts it will not compromise on safety or efficacy standards or seek Emergency Use Authorization based solely on immunogenicity (antibody) data without proof of disease prevention.
• Bourla expressed high optimism that the question is no longer "if" a vaccine will be developed but "when," estimating a high probability of success, though he acknowledges the pressure of global reliance on the pharmaceutical industry.